The grounding of the U.S. space shuttle fleet is taking a toll on research aboard the international space station. U.S. and Russian officials are thinking about sending up two rather than three astronauts when a Soyuz capsule-the only link now to the orbiting laboratory-arrives in May to relieve the current three-person crew. The smaller crew would allow officials to minimize food, air, and water consumption while NASA searches for the reasons behind the recent Columbia disaster.
Russian space chief Yuri Koptev told reporters in Moscow last week that the replacement crew would focus on station maintenance until the shuttles resume their construction duties. "The maintenance of the station is a no less complicated task than its completion," Koptev said. A reduced crew and limited launch capacity could restrict the time available for science to one-third of the amount planned before Columbia's destruction, NASA estimates.
NASA and Russian space agency staffers are considering a two-member crew, confirms NASA spokesperson Debbie Rahn: "We're looking at it very closely to see if it makes sense." Recently, NASA designated one of the three crew members as a science officer to emphasize the importance of station research.
The change would still allow human physiology research, because much of the data collection occurs before and after the mission. But research involving large amounts of material, such as protein crystal growth, would not be possible, says NASA's Peter Ahlf, and there will be less room for product development. "We'll be happy to get [done] one-third or more" of the research planned before the accident, he says, adding that a halt in construction could free up some crew time for research.
Koptev said that Russia may add another unmanned Progress mission, an automated spacecraft that ferries materials, to its scheduled launch this year of two Soyuz and three Progress supply ships. If the shuttle is still grounded next year, he said, a half-dozen Progress launches would be necessary to maintain station operations.
Koptev is hoping that U.S. aid will bolster Russia's perennially cash-strapped space program. But a U.S. law prevents NASA from purchasing additional vehicles unless the White House can certify to Congress that Russian companies are not selling ballistic missile technology to Iran. It also prevents a third party, such as the European Space Agency, from purchasing hardware on behalf of NASA. Although Koptev denies that any sales to Iran are taking place, U.S. officials say that his assertion would be difficult to confirm. At the same time, congressional staffers note that the law provides an exception for safety needs.
Meanwhile, NASA officials and outside researchers continue sorting through data from the 80 experiments aboard Columbia. "We estimate that anywhere between 50% and 90% of the data was acquired" from experiments that beamed their data from the shuttle to satellites to Earth, says David Liskowsky, program scientist for the mission.
Most of that research involved combustion, materials science, and fluid experiments.
For example, about half of the data from an experiment designed to test the mechanics of granular materials, such as sand, was successfully downlinked. And nearly all of the data from an effort to measure changes in the viscosity of xenon-in order to understand complex fluid movement-was returned via satellite.
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Smaller Station Crew Would Put More Pressure on Research C O L U M B I A D I S A S T E R
Crew cut. The next Soyuz mission may ferry only two astronauts to the space station to conserve supplies.
The nation's cancer chief, National Cancer Institute (NCI) director Andrew von Eschenbach, has announced a startling new goal in the battle against cancer. His institute intends to "eliminate death and suffering" from the disease by 2015. The cancer research community is abuzz over the announcement. Some say that however well intended, the goal is clearly impossible to reach and will undermine the director's credibility.
Von Eschenbach, who has headed the $4.6 billion NCI for a year, announced the 2015 target on 11 February to his National Cancer Advisory Board. He told board members that he did "not say that we could eliminate cancer." Rather, he continued, his goal is to "eliminate suffering and death due to this disease." NCI is working on a strategy to do that by discovering "all the relevant mechanisms" of cancer, developing interventions, and getting treatments to patients.
Many researchers have been skeptical of such deadline setting ever since the War on Cancer, President Richard M. Nixon's plan to cure cancer by 1976, failed to deliver. Von Eschenbach's announcement, which reached many people through a report last week in the newsletter The Cancer Letter, drew mixed reactions. Setting a target date is not "necessarily a bad thing," says molecular biologist Phil Sharp of the Massachusetts Institute of Technology. But given the 7 to 10 years it takes to test new therapies in the clinic, "I doubt we're going to be able to accomplish that" in 12 years. Science historian Robert Cook-Deegan of Duke University in Durham, North Carolina, who suggests that deadlines are more suitable for technological challenges such as computing and sequencing the human genome, notes: "I like the spirit of what he's trying to do," but "mak- 
